Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
The latest update is out from Cellectis SA ( (CLLS) ).
Cellectis S.A. released its unaudited interim financial report for the nine-month period ending September 30, 2025. The report, prepared in accordance with International Accounting Standard 34, highlights the company’s financial position and operational results. The document also includes management’s discussion and analysis of financial conditions and results of operations, providing insights into the company’s strategic direction and market positioning. This release is significant for stakeholders as it offers a comprehensive view of Cellectis’s financial health and potential challenges, such as regulatory developments and market competition, which could impact its future operations.
The most recent analyst rating on (CLLS) stock is a Hold with a $3.00 price target. To see the full list of analyst forecasts on Cellectis SA stock, see the CLLS Stock Forecast page.
Spark’s Take on CLLS Stock
According to Spark, TipRanks’ AI Analyst, CLLS is a Neutral.
Cellectis SA’s overall stock score is primarily influenced by its mixed financial performance and positive earnings call sentiment. The company’s strong liquidity and cash management are offset by ongoing profitability challenges. Technical analysis indicates bearish momentum, and valuation metrics reflect the company’s current financial struggles. The positive outlook from clinical trial progress and strategic partnerships provides some optimism, but legal uncertainties and financial challenges remain significant concerns.
To see Spark’s full report on CLLS stock, click here.
More about Cellectis SA
Cellectis S.A. is a biotechnology company focused on developing gene-editing technologies. The company specializes in the development of TALEN® technology and other gene-editing platforms, primarily targeting the healthcare sector to advance therapeutic solutions.
Average Trading Volume: 127,110
Technical Sentiment Signal: Buy
Current Market Cap: $242.1M
See more insights into CLLS stock on TipRanks’ Stock Analysis page.